Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Treatment of hypertension,Management of angina pectoris (chronic stable, vasospastic, unstable),Rate control in atrial fibrillation/flutter,Supraventricular tachyarrhythmias
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
3-4.5 hours; prolonged in hepatic impairment (up to 10 hours) and in elderly
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Extensively metabolized in the liver via CYP3A4; undergoes deacetylation, N-demethylation, and O-demethylation; metabolites include desacetyl-diltiazem (active).
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: 2-4% unchanged; hepatic metabolism with biliary excretion; fecal elimination accounts for ~10%
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
70-80% bound to albumin
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
5-8 L/kg; indicates extensive tissue binding
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral: ~40-50% due to first-pass metabolism; IV: 100%
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No adjustment required for GFR >10 m L/min; for GFR <10 m L/min, use with caution and monitor heart rate.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh Class A: reduce dose to 5-10 mg/hour; Child-Pugh Class B: reduce to 2.5-5 mg/hour; Child-Pugh Class C: avoid use.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Children: 0.25-0.33 mg/kg/hour continuous IV infusion; maximum 15 mg/hour.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly: initial dose at lower end of range (5-10 mg/hour); titrate slowly due to increased sensitivity and risk of bradycardia.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
There is no FDA black box warning for diltiazem.
None
May cause bradycardia and AV block,Concomitant use with beta-blockers increases risk of bradycardia/heart failure,Avoid in patients with left ventricular dysfunction,May worsen heart failure in patients with reduced ejection fraction,Hepatic impairment requires dose adjustment,Monitor renal function in elderly; may cause hypotension,Avoid abrupt withdrawal
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Sick sinus syndrome (except with pacemaker),Second- or third-degree AV block (except with pacemaker),Severe hypotension (systolic <90 mm Hg),Acute myocardial infarction with pulmonary congestion,Hypersensitivity to diltiazem,Concurrent use with ivabradine
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid consumption of grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing diltiazem serum concentrations and risk of toxicity. No other significant food interactions.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times the maximum recommended human dose. Use only if potential benefit justifies risk. First trimester: potential teratogen, avoid unless essential. Second and third trimesters: may cause uterine hypoperfusion and fetal hypoxia due to maternal hypotension; monitor fetal heart rate and uterine activity if used near term.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Diltiazem is excreted into human milk; milk-to-plasma ratio approximately 0.9. Limited data suggest low levels but potential for adverse effects in nursing infants (bradycardia, hypotension). Consider alternatives, especially while nursing a preterm or low-birth-weight infant. If used, monitor infant for signs of bradycardia and hypotension.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance. No established dose adjustment guidelines; use lowest effective dose. Monitor clinical response and titrate cautiously. Consider starting at lower-end doses (e.g., 30 mg PO QID) and increase based on BP and HR. IV use may require more careful titration due to volume changes.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
Diltiazem hydrochloride in 0.72% sodium chloride is an intravenous calcium channel blocker used for rate control in atrial fibrillation/flutter and hypertension. Monitor heart rate and blood pressure closely; may cause bradycardia, hypotension, and heart block. Avoid in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. The 0.72% sodium chloride concentration provides isotonicity; ensure proper IV access to prevent extravasation tissue necrosis. Contraindicated with concurrent beta-blocker use due to additive bradycardic effects.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
This medication is given intravenously to control heart rate or lower blood pressure.,You will have your heart rate and blood pressure monitored continuously during infusion.,Report symptoms of dizziness, fainting, slow heart rate, or difficulty breathing.,Avoid grapefruit juice as it may increase drug levels and side effects.,Do not stop taking other heart medications without consulting your doctor.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Mebendazole, an anthelmintic, inhibits CYP3A4-mediated metabolism of diltiazem, a calcium channel blocker used for hypertension and angina. This results in elevated diltiazem plasma concentrations, increasing the risk of bradycardia, hypotension, and atrioventricular block. Patients may experience enhanced negative chronotropic effects, leading to symptomatic bradycardia or heart block."
"Antipyrine, a substrate of cytochrome P450 (CYP) 3A4, when coadministered with Diltiazem, a moderate inhibitor of CYP3A4, results in decreased metabolic clearance of Diltiazem. This leads to increased plasma concentrations of Diltiazem, potentiating its negative chronotropic and hypotensive effects. Clinically, this interaction may manifest as bradycardia, atrioventricular block, and excessive hypotension."
"Diltiazem, a moderate CYP3A4 inhibitor, can significantly increase the systemic exposure of ceritinib, a sensitive CYP3A4 substrate. This interaction leads to elevated ceritinib plasma concentrations, potentiating its dose-dependent toxicities, including hepatotoxicity, QT interval prolongation, and gastrointestinal disturbances. Concomitant use may require ceritinib dose reduction or temporary discontinuation to mitigate adverse effects."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is a Electrolyte that works by Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes by binding to the L-type calcium channels, leading to coronary vasodilation, decreased myocardial contractility, and slowed AV nodal conduction.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is: Intravenous continuous infusion: 5-15 mg/hour (0.25-0.33 mg/kg per hour).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The metabolism of Diltiazem can be decreased when combined with Aminophylline. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE is classified as Category A/B. No adequate studies in pregnant women. In animal studies, diltiazem has been associated with embryofetal toxicity (skeletal abnormalities, increased mortality) at doses >5 times th. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.